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1. Introduction
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. With
current treatment strategies, almost 80% of AML patients (18-60 years) will achieve com‐
plete remission (CR). However, approximately 50% of these patients will experience a re‐
lapse, resulting in a five-year survival rate of only 35%-40% [1]. This implies that despite CR,
in these patients a number of cancer cells survive treatment and can grow out to cause a re‐
lapse. Efforts towards development of more sensitive methods to accurately determine CR
and detect residual cancer cells are necessary to improve risk-adapted management to even‐
tually prolong overall survival rates.
2. Minimal residual disease and acute myeloid leukemia
In AML patients, morphologic assessment is performed to evaluate chemotherapy response
and to define remission status. By definition, patients are in CR when less than 5% blast cells
are present in the bone marrow (BM) concurrent with evidence of normal erythropoiesis,
granulopoiesis and megakaryopoiesis. In addition, neutrophils and platelets in peripheral
blood should be at least 1.0 x 109/l and 100 x 109/l, respectively [2]. Since about 50% of pa‐
tients in CR will eventually experience a relapse, for prognostic purposes more precise as‐
sessment of the quality of CR is necessary. To this end residual disease detection could be of
high importance. This so-called minimal residual disease (MRD) is thus defined as the per‐
sistence of leukemic cells after chemotherapy treatment and thought to be responsible for
the emergence of relapse (Figure 1). Quantitative MRD frequency assessment could give im‐
portant prognostic information after chemotherapy treatment. Two highly sensitive meth‐
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ods for MRD detection in leukemia are multiparameter flow cytometry (MFC) and real-time
quantitative polymerase chain reaction (RQ-PCR). Both methods and their clinical applica‐
tions will be reviewed in this chapter.
Figure 1. The role of minimal residual disease and leukemic stem cells in the emergence of relapse. HSC, normal hem‐
atopoietic stem cell, LSC, leukemic stem cell. At AML diagnosis a heterogeneous population of cells often coexist, in‐
cluding different subpopulations of LSCs. MRD frequency assessment focuses on the detection of leukemic cells
present after treatment. Different subpopulations of chemotherapy resistant LSCs can grow out and cause relapse
(discussed in section 3).
2.1. Immunophenotypic MRD detection
2.1.1. Principles of immunophenotypic MRD detection
One of the most frequently used techniques to assess MRD in leukemia is based on assess‐
ment of immunophenotypic aberrant antigen expression using flow cytometry. For practical
purposes, in most cases, this approach is restricted to cell surface antigen expression. At di‐
agnosis, so-called leukemia associated (immuno)phenotypes (LA[I]Ps, further referred to as
LAPs) are determined. Such a LAP consists of (an) aberrantly expressed cell surface mark‐
er(s), usually combined with a myeloid marker (CD13/CD33) and with a normal progenitor
antigen, i.e. CD34, CD117 or CD133. LAPs are grouped into (1) cross-lineage antigen expres‐
sion (e.g. expression of lymphoid markers in myeloid blasts), (2) asynchronous antigen ex‐
pression (co-expression of antigens that are not concomitantly present during normal
differentiation), (3) lack of antigen expression and (4) antigen overexpression [3]. Such aber‐
rancies can subsequently be used to detect MRD (Figure 2).
Due to large heterogeneity of immunophenotypes in AML, determination of LAPs has to be
performed for each individual patient. These LAPs are not, or only in very low frequencies,
present on normal BM cells in remission BM. Sensitivities have been reported to be in a
range of 10-3 down to 10-5 (1 leukemic cell in 1,000 to 100,000 normal cells) [4-9]. Besides
these relatively high sensitivities, it is also a very rapid technique. Main advantage of flow
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cytometric MRD assessment is its broad applicability: in 80%-95% of all AML patients one or
more LAPs can be defined. [4,5,9-11]. There are, however, potential pitfalls/disadvantages
that should be taken into account. Firstly, blast cells at diagnosis are often characterized by
subpopulations with different immunophenotypes. For this reason a LAP defined at diagno‐
sis, is often not a characteristic of the total population of leukemic blast cells. Since only the
LAP positive (LAP+) cells can be identified at follow-up, this may thus result in under-esti‐
mation of cell frequency of all leukemic blast cells, referred to as MRD. To approach the real
MRD cell frequency, there is the possibility to correct LAP+ frequency at follow-up for the
LAP+ frequency, as percentage of blasts, at diagnosis. Secondly, the presence of low percen‐
tages of normal cells that express a particular LAP may result in over-estimation of MRD
cell frequency. This background staining may even lead to false-positive results. A relatively
low background staining can be achieved by including a primitive marker in the definition
of a LAP, since these cells are only present at low frequencies in normal BM. Thirdly, immu‐
nophenotypic shifts may occur in the course of treatment and result in false-negativity
[6,12,13]. To avoid this, it is recommended to use multiple LAPs. Finally, due to the large
number of different LAPs, MRD analysis is quite complex and needs vast experience in dis‐
criminating leukemic cells from cells with normal differentiation patterns.
Figure 2. Example of MRD detection in BM using the aberrant phenotype of CD34+CD7+ cells at AML diagnosis (A-C)
and during follow-up (D-F). Gating of the blast cells with CD45dim expression and low sideward scatter (SSC) (A, D),
gating of the CD34 positive progenitors cells (B, E) and gating of the leukemic blast population with aberrant expres‐
sion of CD7 on the myeloid progenitor cells (C, F). After chemotherapy treatment a residual population of leukemic
blasts can be detected (F).
2.1.2. Prognostic value of immunophenotypic MRD in bone marrow
The likelihood of achieving CR after therapy and the duration of CR depend on different fac‐
tors. Important prognostic risk factors available at diagnosis are: history of previous leukemia
or myelodysplastic syndrome, age, white blood cell (WBC) count, percentage of BM blast cells
and the presence of particular cytogenetic and/or molecular aberrancies [14]. Besides these
pre-treatment prognostic factors, it is suggested that MRD detection in BM shortly after treat‐
ment offers an important post-treatment prognostic factor. To evaluate the impact of MRD fre‐
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quencies on relapse rate and overall survival (OS), MRD was related to outcome parameters
using survival analyses such as Kaplan Meier curves. For these analyses, most studies set a
threshold to define MRD negative (or low) and MRD positive (or high) patients. Different lab‐
oratories use different optimal cut-off values after both induction and consolidation therapy
(Table 1). However, it should be emphasized that usually, it is not a single cut-off point, but a
range of cut-off values that significantly predict clinical outcome.










Feller et al. 52 0.14% 0.11% [6]
Kern et al. 62 Log difference 1.70 Log difference
2.94
[5]
Maurillo et al. 142 0.035% 0.035% [16]
Al-Mawali et al. 54 0.15% 0.15% [10]
Table 1. Overview of studies in adult AML with cut-off values used for analyzing relapse free and overall survival.
San Miguel et al. were the first to show the prognostic impact of MRD in a group of 53 AML
patients [4]. Later they extended the study to 126 patients. An overview of three-year relapse
rates for three distinct patient risk groups with considerable patient numbers is given in Ta‐
ble 2. Univariate analysis of prognostic factors revealed five disease characteristics that had
significant impact on relapse-free survival (RFS); these included cytogenetic abnormalities,
number of chemotherapy cycles needed to achieve CR, WBC count, absolute peripheral
blood (PB) blast cell count and MRD levels. In a multivariate analysis only cytogenetics (p =.
03) and MRD levels (p =.002) were independent prognostic factors for RFS [15]. These results
are in line with other studies. Results from Feller et al., showed a relative risk of relapse of
3.4 after induction therapy (p =.003) and 7.2 after consolidation therapy (p =.004) in the pa‐
tient group with high MRD levels [6].
MRD level Patients (n) Relapse rate ± standard error
< 0.1 % 16 9% ± 7%
0.1% - 1% 45 56% ± 9%
"/1% 21 83% ± 10%
Table 2. Overview of three-year relapse rates for three distinct risk groups based on MRD levels determined after
induction therapy (p =.006) [15].
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Al-Mawali et al. demonstrated in a multivariate analysis that post-induction positive MRD
status was an independent prognostic factor for both RFS and OS (p =.037 and p =.026, re‐
spectively) MRD positivity after induction therapy was also associated with increased risk
of relapse (Hazard ratio [HR] 4.7, 95% confidence interval [CI] 1.1-20.5) [10]. Maurillo et al.,
in a study following their original report [7], have reported similar results in a study of 142
AML patients. In a multivariate analysis of RFS, cytogenetics (p =.0001), multidrug resist‐
ance-1 phenotype (p =.03) and MRD positivity after consolidation therapy (p =.001) were in‐
dependent prognostic factors. In multivariate analysis of OS, post-consolidation MRD
positivity (p =.004) was the only independent prognostic factor [16]. Kern and colleagues, in
an approach that established log reduction of blast cells as a measure for MRD, showed that
after induction therapy < 1.7 log reduction (p =.006) and unfavorable karyotype (p =.0001)
were independent prognostic factors for relapse [5]. After consolidation therapy < 2.94 log
reduction (p =.006) and unfavorable karyotype (p =.015) were found to be independent fac‐
tors for relapse. Although above-mentioned study results are promising and consistent, the
clinical importance of MRD in adult AML still has to be validated in a prospective study.
Terwijn et al. studied the value of MRD monitoring in a large cohort of 462 AML patients.
Multivariate analysis, performed with conventional prognostic factors, demonstrated that
MRD frequency was an independent prognostic factor for RFS after every cycle (first cycle p
=.010, second cycle p<.00001 and consolidation p<.00001) and for OS after the first cycle (p =.
023) and second cycle (p =.01). To our knowledge, this is the first study that demonstrates
the importance of MRD monitoring in a prospective study [17]. Because of these prospective
data, the next step would be to implement MRD status in clinical decision-making.
2.2. Molecular MRD detection
Although flow cytometry is an attractive technique for MRD detection, the limitations, in‐
cluding background staining, immunophenotypic switches, complexity of analysis and LAP
expression on only part of the leukemic cells, give rise to alternative approaches for MRD
detection, including molecular MRD monitoring using the Polymerase Chain Reaction
(PCR) technique. This approach allows for the detection of mutations, translocations, inver‐
sions, deletions and polymorphisms. Real-time-(qRT-) PCR is the most sensitive technique
for MRD detection: it allows detecting MRD with sensitivities that have been reported in a
range of 10-4 to 10-6 [18-21]. QRT-PCR is now extensively being studied as approach for MRD
detection. Common targets for molecular MRD monitoring, including fusion genes, overex‐
pressed genes and gene mutations, will be reviewed in this section.
2.2.1. Fusion genes
Fusion genes are among the best potential targets for molecular MRD detection. In AML the
most common chromosomal rearrangements, producing fusion genes, are t(8;21), t(15;17) and
inv(16)/t(16;16).  The  corresponding  fusion  genes  are  AML1-ETO,  PML-RARα  and  CBFβ-
MYH11, respectively. Depending on geographics, these occur in about 15%-45% of all AML
cases and are associated with favorable prognosis [22]. Molecular MRD studies performed for
AML1-ETO and CBFβ-MYH11 are relatively scarce and have included relatively few patients.
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In t(8;21) rearrangement, the AML1 gene on chromosome 21 fuses with the MTG8(ETO)
gene on chromosome 8 to produce the fusion gene AML1-MTG8, also called AML1-ETO [23].
Tobal et al. studied 25 t(8;21) patients and demonstrated a 2 to 3 log reduction in the level of
AML1-MTG8 after induction chemotherapy and a further 2 to 3 log reduction after consoli‐
dation therapy. In all patients with durable CR (n = 20), AML1-MTG8 transcripts levels in
BM were ≤ 1 x 103 molecules/μg (median 227 molecules/μg). On the other hand, levels of ≥
0.71 x 105 molecules/μg were predictive of relapse within 3 to 6 months (n = 5, median 1.49 x
105 molecules/μg) [24]. Krauter et al. retrospectively studied 37 AML patients with t(8;21) (n
= 22) or inv(16) (n = 15) using RT-PCR. Levels of AML1/MTG8 and CBFβ/MYH11 were quan‐
tified relative to expression of a housekeeping gene. This resulted in significantly lower
MRD levels in non-relapsing patients (median 0%, range 0%-1.5%) compared to patients
who did experience relapse (median 0.14%, range 0%-15.6%, p<.01). Furthermore, RFS was
significantly shorter in patients with high MRD levels (≥ 1% of the pre-treatment value)
compared to patients without relapse (p<.001), with a similar trend for OS (p = 0.12) [25].
Guerrasio et al. retrospectively studied a cohort of 16 AML patients with CBFβ/MYH11 rear‐
rangements. Analysis in first CR revealed a significantly higher mean copy number of CBFβ/
MYH11 transcripts in patients who relapsed (mean 151) than in patients with stable remis‐
sion (mean 9, p<.0001) [20]. Buonamici and colleagues also retrospectively studied 21 pa‐
tients with inv(16) rearrangements and found that patients who relapsed always had CBFβ/
MYH1:control ratios > 0.12% during CR (median 0.54%, range 0.12%-7.1%). Patients without
subsequent relapse, on the other hand, always had ratios < 0.25% (median 0%, range
0%-0.25%), suggesting a cut-off point of 0.25% above which relapse is probable. Despite
these promising results, two patients with MRD levels below the cut-off of 0.25% still experi‐
enced a relapse [26]. It thus seems that quantitation of both AML1/MTG8 and CBFβ/MYH11
can detect important changes in the level of fusion transcripts and that it can give prognostic
information. However, it is important that these results still have to be confirmed in larger
studies. Despite the advantages, MRD monitoring using AML1/MTG8 and CBFβ/MYH11 is
possible in only a minority of AML patients.
More research has been done on the PML-RARA transcript in acute promyelocytic leukemia
(APL). Although the outcome for APL patients has significantly improved with the develop‐
ment of targeted therapies, including all-trans-retinoic acid (ATRA) and arsenic trioxide
(ATO), still 10%-15% of APL patients will suffer from relapse. Therefore MRD monitoring to
predict clinical outcome could also be of importance in this subgroup of AML patients. In a
large prospective study, including 406 APL patients, MRD, monitored by PML-RARA tran‐
script analysis, was used to direct pre-emptive therapy with ATO and to guide use of trans‐
plantation. In this study, MRD was identified as most powerful prognostic factor for RFS
(HR 17.87, 95% CI 6.88-46.41, p<.0001) in a multivariate analysis. Furthermore, increases in
PML-RARA transcript levels were used to guide pre-emptive therapy and this resulted in a
cumulative relapse incidence of only 5% at 3 years [27]. This showed that detection of APL
fusion transcripts after chemotherapy treatment is a valid strategy for MRD guided pre-
emptive therapy, a strategy that allows reduction of relapse rates. This approach, however,
is only applicable in approximately 5%-30% of AML patients.
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Mixed-lineage leukemia (MLL) fusion genes, which are the result of 11q23 rearrangements,
occur in around 10% of both acute lymphocytic leukemia (ALL) and AML and are associat‐
ed with adverse clinical outcome [28,29]. MRD detection using MLL transcripts is challeng‐
ing, since up to 50 different translocations, resulting in different MLL fusion genes, have
been described. Most common 11q23 abnormalities are t(9;11)(p22;q23), t(11;19)(q23;p13.3)
and t(6;11)(q27;q23) [30]. Mittelbauer et al. studied 209 patients at AML diagnosis and de‐
tected MLL gene rearrangements in 27 patients (12.9%). The MLL-AF6 fusion transcript,
caused by t(6;11)(q27;q23), was detected by RT-PCR in 6 of those 27 patients. All 6 patients
achieved hematological CR, however, only one patient achieved molecular CR and that pa‐
tient was still in stable CR 33 months after diagnosis. The other 5 patients did not reach mo‐
lecular CR and they all relapsed 2.6-8.3 months after achieving hematological CR. The
authors suggest that a reduction of positive blasts below the RT-PCR detection limit of 10-5
to 10-6 seems to be a prerequisite for long term CR. Unfortunately the incidence of MLL-AF6
was only 3% in the whole group of 209 patients, resulting in low applicability of this assay
[21]. To summarize, levels of MLL fusion transcripts may be useful to evaluate treatment re‐
sponse and predict clinical outcome. However, large prospective studies have to be per‐
formed to confirm the clinical importance. A major drawback is the limited applicability due
to the relatively low incidence of 11q23 rearrangements, also characterized by high numbers
of different translocations.
2.2.2. Overexpressed genes
Since in only a small fraction of patients, fusion transcripts are present, overexpressed genes
might offer a potential alternative target for molecular MRD monitoring. Such overex‐
pressed genes are either silenced or expressed at very low levels in normal hematopoietic
cells. Commonly overexpressed genes are WT1, EVI1 and PRAME. In particular for WT1,
which has originally been described in the development of Wilms tumor [31], multiple stud‐
ies have been performed. This gene was shown to be also highly expressed in leucocytes of
several hematopoietic malignancies, including AML [32,33]. Although the mechanisms of
this overexpression are poorly understood, WT1 overexpression could be a suitable candi‐
date as molecular marker for MRD monitoring. However, the potential use of this marker
may be hampered by the overexpression of WT1 in normal regenerating BM [34-36]. In a
large study by Cilloni et al., 504 patients were studied at diagnosis and WT1 was found to be
overexpressed in 86% of the cases. Of these, 129 patients were analysed during follow-up
and it was demonstrated that after the first chemotherapy cycle a larger than 2-log reduction
in WT1 levels was an independent prognostic factor for decreased risk of relapse (HR 0.54,
range 0.36-0.83, p =.004). After consolidation therapy low WT1 levels also predicted de‐
creased risk of relapse (p =.004) [37]. Hämäläinen and co-workers analysed WT1 expression
at diagnosis in BM of 100 AML patients and found no prognostic significance as such (cut-
off 9.7%, compared with K562 cell WT1 gene expression). Although WT1 expression levels
were constantly detectable during the remission period, they nevertheless found that an in‐
crease in WT1 expression levels may be a predictor for relapse [38]. Although these results
show that WT1 overexpression for MRD monitoring is a potentially useful marker that can
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be used in the majority of AML patients, despite multiple studies having been performed,
the clinical utility of WT1 monitoring remains somewhat controversial [37,38].
Another potential marker is PRAME, a gene originally recognized in melanoma patients,
which is expressed in 35%-64% of AML patients [39-41]. In a study by Qin et al., using BM
material from 204 newly diagnosed patients, PRAME overexpression was found in 55.4% of
the cases. In follow-up patients who achieved continuous haematological CR (n = 20),
PRAME levels had decreased but never reached the normal range in 6/20 patients. All of
these patients ultimately relapsed. In seven patients PRAME levels decreased down to nor‐
mal levels, but thereafter rose again above normal values; all of these patients eventually re‐
lapsed within 4 months. In the remaining patients (7/20) PRAME levels decreased down to
the normal range and these patients remained in continuous CR. This suggests that the
PRAME gene may be a useful marker for MRD monitoring [42]. Although these results are
promising, a few potential pitfalls should be taken into account. Both WT1 and PRAME are
expressed in relatively high levels in normal hematopoietic cells, which result in high levels
of background expression before and after treatment. WT1 and PRAME are thus not highly
specific markers, with risk on false-positive results [37,38]. To avoid this, PB may be used as
an alternative source of cells, since both WT1 and PRAME levels are much lower in circulat‐
ing normal PB cells, than in normal BM cells [37,42]. Furthermore, a more general disadvant‐
age for gene overexpression is the risk of RNA degradation during isolation procedures that
might result in false-negativity. Since overexpression of WT1 is more frequent in AML cells
than PRAME, WT1 is probably the most useful target for MRD monitoring.
The ecotropic virus integrations-1 (EVI1) proto-oncogene is associated with chromosome
3q26 rearrangements and high expression at diagnosis predicts poor clinical outcome [43].
EVI1 overexpression has been demonstrated in approximately 8% of the AML patients [44].
To our knowledge, no MRD studies using EVI1 overexpression have been performed thus
far. At least 4 different splice forms have been identified (EVI1-1A, -1B, -1C and -3L) [45].
Seen the low frequency of cases with overexpression, EVI1 based MRD detection would add
significantly to MRD detection if all splice variants could be detected. Since EVI1 positive
patients have an extremely poor prognosis it may be suggested that MRD based pre-emp‐
tive therapy in EVI1 positive patients would allow therapeutic intervention at an earlier time
point and thereby possibly improve clinical outcome. Future studies will have to confirm if
EVI1 is indeed a useful and stable MRD marker.
2.2.3. Gene mutations
Since fusion genes are only present in 15%-45% of AML patients and overexpressed genes
seem to be less specific MRD markers, gene mutations may offer another attractive group of
targets for MRD monitoring.
A decade ago, fms-like tyrosine kinase 3 (FLT3) mutations were found to be present in ap‐
proximately 30% of AML patients. Different FLT3 mutations exist; however, the most com‐
mon is the FLT3-internal tandem duplication (ITD) in the juxtamembrane region. This ITD
results in an extra sequence that varies between 3 and 400 base pairs and is thought to cause
a constant activation of the tyrosine kinase receptor, resulting in advantages for cell surviv‐
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al. The FLT3-ITD occurs in approximately 23% of adult AML patients and is associated with
poor prognosis [46-48]. Since FLT3-ITD is suggested as potential MRD marker, several stud‐
ies have been performed to confirm this. Chou et al. demonstrated that both OS and disease
free survival (DFS) were significantly longer in CR patients who obtained a > 3-log reduc‐
tion compared to the CR patients with less reduction (OS not reached v. 14.7 months, p =.
016, DFS 7.5 v. 3.0 months, p<.001). Moreover, a > 3-log reduction of FLT3-ITD was an inde‐
pendent prognostic factor for DFS (HR 0.264, p =.002) with a trend for OS (HR 0.308, p =.057)
[49]. Thus, MRD monitoring by FLT3-ITD can provide prognostic information [49-52]. How‐
ever, a serious limitation of the use of a FLT3-ITD, is its instability during disease. In part of
the AML samples that harbor a FLT3-ITD at diagnosis, it has changed or disappeared at re‐
lapse [49,53-55], which would result in false-negative MRD results. Furthermore, because of
the heterogeneity in FLT3-ITD lengths and molecular sequence, no common qRT-PCR can
be developed, which offers a serious problem in regular diagnostics [46,51,56].
Mutations in the nucleophosmin (NPM1) gene have also been identified as frequent genetic
alterations, occurring in approximately 35% of all AML patients. This mutation occurs most
frequently in exon 12 of the gene, resulting in loss of one or both C-terminal tryptophan resi‐
dues leading to an aberrant localization of the protein in the cytoplasm [57,58]. The presence
is strongly associated with a normal karyotype, where NPM1 mutations occur in approxi‐
mately 60% of patients [59]. When not accompanied by a FLT3 mutation, it has been descri‐
bed as a favorable factor in patients with normal cytogenetics [60,61]. Quantitative
monitoring of NPM1 mutations after treatment has shown to give important prognostic in‐
formation [50,62-66]. Although stability of this marker has been reported in several studies
[50,62,63,65], loss of the NPM1 mutation at relapse has also been found [67,68]. It has to be
taken into account that more than 30 different types of NPM1 mutations have been descri‐
bed, but fortunately two types (type A and type B) are by far the most common [57,58]. It
can be concluded that MRD assessment by NPM1 mutations is a suitable, stable and sensi‐
tive marker. However, more prospective studies are warranted to validate these results and
to confirm stability of NPM1 during disease.
CCAAT/enhancer binding protein alpha (CEBPα) is a transcription factor involved in the
regulation of myeloid differentiation and cellular growth arrest [69]. CEBPA mutations have
been reported in 8% to 19% of cytogenetically normal AML patients and are associated with
favorable prognosis [70-72]. There are two major types of CEBPA mutations, including C-
terminal mutations that occur in the bZIP domain and N-terminal mutations. Furthermore,
some patients carry biallelic mutations, whereas others are heterozygous for different kind
of mutations [72]. Although CEBPA is a potential suitable target for MRD monitoring, to our
knowledge, no studies have been reported thus far. Seen the low frequency of cases with a
CEBPA mutation, CEBPA based MRD detection would have limited applicability in AML
patients. Future clinical trials have to demonstrate if CEBPA is indeed a suitable and stable
marker for MRD detection.
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2.3. Clinical applications of MRD
As discussed above, MRD frequency assessment using immunophenotypic and molecular pa‐
rameters in patients with AML in clinical remission has important prognostic value and can
predict forthcoming relapses. Therefore, it would be of potential importance to monitor MRD
cell frequency for risk stratification. Current AML risk stratification is based on a number of
parameters determined at diagnosis, including origin of leukemia (secondary AML, AML af‐
ter myelodysplastic syndrome), age, WBC count, and presence of certain cytogenetic and/or
molecular aberrancies [14]. Novel AML risk stratification should not only be based on risk as‐
sessment at diagnosis, but also on MRD cell frequency as a “response to treatment” parame‐
ter. Including MRD in AML risk stratification could help identify CR patients after induction
therapy with increased MRD levels and therefore high risk of relapse. For instance, good risk
patients with high MRD levels after induction therapy may benefit from allogeneic stem cell
transplantation, while on the other hand intermediate risk group patients with low MRD lev‐
els could be spared from an allogeneic transplantation and the accompanying toxicity. Espe‐
cially in this intermediate risk group, MRD monitoring would be of great help, since the
prognosis of these patients is difficult to estimate. Therefore, MRD based clinical decision mak‐
ing after induction therapy may contribute to better RFS and OS rates.
Also after consolidation therapy, MRD based clinical intervention is promising. Even after
an allogeneic transplantation, still a proportion of 20%-40% of the patients will relapse
[73-75]. Therapeutic options in the case of post-transplant relapse consist of withdrawal or
decrease of dose of immune-suppressive drugs, or immunotherapeutic intervention with a
donor lymphocyte infusion. As these approaches intend to boost the graft versus leukemia
effect, they are most effective when the leukemic cell load is small. Therefore early detection
of impending post-transplant relapses is essential and would allow immunotherapeutic in‐
tervention at a low leukemic burden. The current standard to guide post-transplant treat‐
ment is the level of donor chimerism. This refers to the percentage of donor cells in PB or
BM and it can be determined using short tandem repeat (STR)-PCR. Although mixed chi‐
merism (< 95% of donor cells) has been associated with a higher incidence of relapse [76,77],
patients with full chimerism (> 95% donor cells) can still suffer from relapse [77]. Additional
monitoring of MRD levels in these transplanted patients could improve successful predic‐
tion of relapse, since MRD analysis directly detects the neoplastic part of the patient cell
population, while STR analysis reflects total donor and total patient populations. Multiple
studies have shown that MRD monitoring after an allogeneic transplantation indeed corre‐
lates with clinical outcome and identifies patients who are likely to relapse [78-81]. There‐
fore, it can be suggested that MRD based pre-emptive immunotherapy after transplantation
could reduce relapse and improve survival. Standardization of treatment, based on MRD
and chimerism analysis in the post-transplant period, seems therefore warranted. In conclu‐
sion, since MRD frequency assessment gives important prognostic information after both in‐
duction and consolidation therapy, it seems likely that using MRD for therapeutic
intervention in the post-remission phase might reduce relapse rates en prolong OS. To con‐
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firm this hypothesis, large prospective studies with MRD based clinical intervention in the
post-remission phase are essential.
2.4. Improvement of and alternatives for bone marrow MRD detection
2.4.1. Improvements for immunophenotypic and molecular MRD detection
Although flow cytometric MRD monitoring has many advantages, one of the difficulties is
the complexity of MRD analysis. Nowadays, more advanced data analysis programs, that
aid to distinguish between normal and malignant cells, are available [82]. This might simpli‐
fy the analysis and result in more objective results. Notwithstanding the high prognostic
value of MRD monitoring, in almost all studies 20%-40% of the patients with immunophe‐
notypic defined low MRD levels still suffer from a relapse [5-7,10,16]. There are several po‐
tential reasons for missing these MRD cells. Normal BM cells express LAPs at low
frequencies. Counting these cells as leukemic might result in false-positivity. This back‐
ground expression thus seriously hinders specific identification of leukemic cells. On the
other hand, subtracting background levels might under-estimate MRD frequencies and this
could result in false-negatives. High specificity and thereby high sensitivity can be achieved
when only the most specific immunophenotypic aberrancies are used, i.e. with no expres‐
sion in normal cells. Inclusion of markers/marker combinations that allow excluding non-
specific events in a multi-color approach may increase specificity. This is already shown for
the transition of a four to five-color flow cytometric approach [83]. Another explanation for
MRD misclassification is low sensitivity of the aberrant immunophenotype. Marker expres‐
sion may be highly heterogeneous in an AML sample: LAPs may thereby often not be ex‐
pressed on the total population of blast cells, thereby, at follow up, preventing the
identification of all leukemic cells. Improvements can only be expected with the discovery of
new aberrancies that cover larger parts of diagnosis blast cells. At present, with the large dif‐
ferences in specificity and sensitivity of LAPs the level of detection of MRD varies between
patients: 1:10,000 or even better may be reached in one patient, while in another patient
1:1,000 may be the best attainable. Besides misclassification, immunophenotype shifts can al‐
so contribute to false-negative observations. To reduce this, it is recommended to use multi‐
ple LAPs for MRD monitoring [6,12,13]. Recently, it has become clear that such shifts may
occur through clonal selection: while major molecular clones may disappear upon therapy,
minor diagnosis clones may survive chemotherapy treatment, and grow out to relapse [84].
This may be accompanied by immunophenotype changes [84]. More efforts towards recog‐
nition of minor clones at diagnosis, that potentially can expand to cause relapse, may identi‐
fy emerging molecular clones and immunophenotypes instead of disappearing molecular
clones and immunophenotypes only. For molecular MRD, in fact most of the pitfalls for im‐
munophenotypic MRD hold here as well. Similar to MFC, multiple molecular MRD studies
have reported patients with low molecular MRD levels that still suffer from relapse
[25,26,37,38,42]. Underlying causes may include 1) as argued earlier for different LAPs, Q-
PCRs for different mutations and fusion genes reach different sensitivities as well; 2) part of
the blasts may only be characterized by the molecular aberrancy of interest; and 3) molecu‐
lar clone shifts occur between diagnosis and relapse. To avoid these false-negative results
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different molecular markers, if present in the patient, could be quantified for MRD monitor‐
ing. There are no real solutions for these problems unless more generally applicable, specific
and stable markers are discovered. Until then, combining as many molecular and immuno‐
phenotypic targets may contribute to accurate MRD based prediction of relapse. Another
possible explanation for finding false-negative MRD results is the fact that it may not only
be the number of leukemic blasts that determines the chance for relapse, but more specifical‐
ly the number of leukemic stem cells (LSCs). These LSCs can cause tumor outgrowth, there‐
by leading to MRD and finally resulting into overt disease relapse [85]. Although these stem
cells are much less frequent than whole blast MRD, LSC frequency assessment may offer an
additional specific and biologically relevant determinant of risk on relapse. In section 3 the
role of leukemic stem cells in acute myeloid leukemia will be further discussed.
2.4.2. Alternative parameters for risk stratification
Perhaps the conceptually simplest method to evaluate treatment response is calculating the
decrease rate of peripheral blasts shortly after treatment. As shown previously for childhood
acute lymphocytic leukemia [86], this may directly reflect the chemosensitivity of individual
patients. The big advantage would be that it is applicable independent of the initial immu‐
nophenotype of the blasts. To accurately calculate such a blast cell decrease rate, blast fre‐
quencies have to be measured every day of chemotherapy treatment. Lacombe et al.
reported two different modalities to evaluate blast cell decrease: 1) calculation of the blast
cell decrease slope by linear regression between day 0 and the first day when at least 90% of
the initial blast load has disappeared, 2) assessment of the total time period needed to reach
90% blast decrease. All patients (n = 74) who reached a 90% blast reduction within 6 days
achieved CR. The authors also showed a strong correlation for both modalities with pa‐
tients’ clinical outcome [87]. Since leukemic blasts at diagnosis in most cases are present in
the PB too, it has been proposed that PB may represent an alternative specific source for im‐
munophenotypic MRD detection. Since aspiration of BM is an invasive procedure, MRD de‐
tection in the PB would offer significant advantages over BM-MRD both for patients and
physicians. Furthermore, the BM contains immature normal populations that resemble
LAPs, while these are thought to be largely absent in PB. The latter would clearly have ad‐
vantages for the easiness of interpreting MRD. Although MRD frequencies in PB are lower
than in BM, PB-MRD frequencies correlated with BM-MRD frequencies and turned out to
have prognostic value [88]. Once the value of PB-MRD is validated in other studies and once
it has been confirmed that BM-MRD is positive in all PB-MRD positive cases, PB-MRD may
replace BM-MRD, provided that PB is MRD positive. In case of PB-MRD negativity, it will
probably remain necessary to perform BM acquisition, since BM-MRD is more sensitive. An‐
other alternative parameter for risk stratification is the presence of B-lymphocyte precursors
in AML BM. A high level of B-lymphocyte precursors after first CR thereby predicts for DFS
[89]. Furthermore, an abnormal high CD34+ myeloid / CD34+ lymphoid ratio (≥ 10) is associ‐
ated with worse outcome [90]. The development of an algorithm including not only BM-
MRD, but also other parameters, including PB-MRD, blast reduction rate, CD34+ myeloid/
lymphoid ratio and the percentage of B-lymphocyte precursors, may contribute to improved
accurate prediction of relapses.
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3. Leukemic stem cells and acute myeloid leukemia
3.1. Definition of leukemic stem cells
It was hypothesized that a small population of cells, distinct from the bulk of tumor cells, is
responsible for tumor initiation and growth in various cancers, including AML [91,92].
These cells are referred to as leukemic stem cells (LSCs) or leukemia-initiating cells (LICs). It
is assumed that similar to normal hematopoiesis, leukemia is hierarchically structured. In
many respects LSCs resemble normal hematopoietic stem cells (HSCs). Similar to HSCs,
LSCs are defined by their ability to undergo self-renewal and the capacity to differentiate to
a limited, although highly variable, extent [93,94]. Furthermore, the immunophenotype of
LSCs resembles the immunophenotype of normal HSCs. The majority of HSCs are present
in the CD34+CD38- immunophenotypic compartment [95,96] and initial AML studies dem‐
onstrated leukemia initiating capacity also to be in the CD34+CD38- compartment [97]. This
small subpopulation of CD34+CD38- cells was able to engraft and cause leukemia in non-
obese diabetic/sever combined immune-deficient (NOD/SCID) mice. These cells were
present at a frequency of only 0.2 to 100 cells per 106 mononuclear cells [97]. Nowadays it is
known that AML LSCs can also reside within the CD34+CD38+ or the CD34- immunopheno‐
typic compartment [98-102]. There is growing evidence that the transformation of a normal
human cell into a LSC not only can occur in a normal HSC, but also in a normal progenitor
cell [103]. Mutations in a normal progenitor cell may confer self-renewal properties to pro‐
genitors. A recent study demonstrated that CD34+CD38- LSCs, despite the immunopheno‐
typic similarities with normal HSCs, are most related to normal progenitors instead of
normal stem cells [102]. In addition, it has been demonstrated that within a patient, the pool
of LSCs at diagnosis is often largely heterogeneous. This implies that different subpopula‐
tions of LSCs often coexist at diagnosis [84,101] (Figure 1). In CD34 positive patients often
both CD34+CD38- cells, CD34+CD38+ and CD34- cells are present and all are able to show leu‐
kemic engraftment when infused separately in NOD/SCID mice. However, no information
exists on possible competition between these compartments in leukemogenesis. Moreover,
the CD34+CD38- compartment has been shown to be less immunogenic compared to the oth‐
er compartments [104], which may explain why it was almost exclusively the CD34+CD38-
compartment that engrafted in NOD/SCID mice with residual immunity [97], while in the
severely immunocompromised later mouse models, the other compartments engrafted as
well. In CD34 negative AML by definition, the CD34- compartment and in particular the
CD34-CD38+ compartment contain LSCs [100]. For clinical treatment and patient survival it
is important to know which putative LSC will survive therapy. In that respect it is important
to realize that the CD34+CD38- compartment has been shown to be most therapy resistant in
vitro [104]. In line with this, it has been reported that in CD34 positive relapsed patients a
CD34+CD38- subpopulation is most likely to survive chemotherapy treatment and expand
towards development of relapse [84].
In the course of time other compartments enriched for LSCs have been identified. These are
based on functional properties and include aldehyde dehydrogenase (ALDH) activity and
drug efflux (Hoechst) capacity. ALDH is a group of cytosolic enzymes that catalyze the oxi‐
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dation of aldehydes. It plays an important role in the retinoid metabolism, since it is re‐
quired for the conversion of retinol (Vitamin A) to retinoic acids. For maturation, loss of
quiescence and differentiation of HSCs, these retinoic acids are important [105,106]. Further‐
more, ALDH activity is supposed to protect cells from the toxic effects of cyclophosphamide
and therefore high ALDH expression in leukemic cells may play a role in chemotherapy re‐
sistance [107,108]. Recently it has been shown that leukemic cells and normal hematopoietic
cells differ in ALDH activity. Normal stem- and progenitor cells have high ALDH expres‐
sion [109-112]. It has to be emphasized that it has recently been demonstrated that the popu‐
lation of cells with intermediate ALDH activity appeared to be enriched for leukemic
CD34+CD38- cells [113-115]. Several authors have confirmed the leukemia initiating capacity
of these cells in NOD/SCID mice [116-118].
Another functional stem cell compartment is the so-called side population (SP). These SP
cells are primarily defined by their capability of efficient Hoechst 33342 dye efflux and espe‐
cially by the way in which fluorescence emission of Hoechst is recorded. In normal BM a
population of CD34+CD38- cells was found in the SP [119,120]. In AML, it has been demon‐
strated that the SP compartment contains a heterogeneous population of cells, containing
HSCs, LSCs, LSC progenitors and early lymphocytes [121]. AML SP cells have shown to be
able to initiate acute leukemia in NOD/SCID mice [122,123]. All these immunophenotypic
and functional findings are important for gaining insight in the process of leukemogenesis
and especially for the development of new therapies aiming at eradication of LSCs.
Besides the ability of LSCs to initiate and sustain the initial AML, there is increasing evi‐
dence pointing towards the importance of LSCs in the occurrence of MRD and the emer‐
gence of a relapse. LSCs are thought to be more resistant to standard chemotherapy
compared to the total population of malignant blast cells and therefore these LSCs are able
to escape apoptosis. Other essential LSC features are their acquired capacity for self-renewal
and proliferation. Such properties allow LSCs to survive chemotherapy treatment, to divide
and to grow out and cause a relapse (Figure 1). Consequently, identification and characteri‐
zation of LSCs is fundamental to gain insight in the mechanisms that underlie relapse and
how to evade relapse.
3.2. Identification of leukemic stem cells
Since the assumed role of LSC in the emergence of an AML relapse, identification of these
probably most malignant cells becomes imperative. The hypothesis would thus be that
quantitation of LSCs in AML patients would give important information about treatment re‐
sponse and risk of relapse. Similar to MRD identified by flow cytometry, LSCs in BM can be
identified using cell surface antigen expression. As mentioned before, LSCs can reside in dif‐
ferent immunophenotypic compartments, but, as argued before, the CD34+CD38- defined
LSCs may be most malignant/resistant [84,104]. Since both HSCs and LSCs reside within this
compartment, discrimination between CD34+CD38- HSCs and LSCs is challenging. Immuno‐
phenotypic LSC detection is often possible making use of the fact that the lineage marker
combinations used for MRD detection, are frequently aberrantly expressed on CD34+CD38-
cells too [124]. These lineage markers include CD2, CD7, CD11b, CD13, CD15, CD19, CD22
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CD33, CD56 and HLA-DR. Combinations of lineage markers could also be used, like
CD33+CD13- and CD15+HLA-DR-. Besides these lineage markers, a growing number of other
markers is now available to discriminate between LSCs and HSCs. These include CLL-1
CD25, CD32, CD33, CD44, CD47, CD96, CD123 and TIM-3 (Figure 3). An overview of LSC
markers is given in Table 3.
Figure 3. Gating strategy for CD34+CD38- LSC detection at diagnosis in AML bone marrow. Gating of viable white
blood cells (A). Gating of blast cells with CD45dim expression and low sideward scatter (SSC) (B, C). CD34 positive pro‐
genitors cells (D). Gating of the CD34 positive and CD38 negative blasts (E). The CD34+CD38- cells gated against CLL-1.
Two populations of stem cells are shown: a CLL-1 negative stem cell population, containing the HSCs and the
CD34+CD38- cells with positive expression of CLL-1. These stem cells with aberrant expression of CLL-1 are defined as
LSCs (F).
It is important to realize that there is a large heterogeneity in marker expression. This im‐
plies that marker expression differs between AML patients and even within an individual
patient different stem cell markers are often differentially expressed (Figure 4). Thus, none
of the individual markers are expressed in all AML cases. For accurate LSC detection, high
specificity of stem cell markers is essential. Both CLL-1 and lineage markers have proven to
be highly specific, since these are present on leukemic CD34+CD38- cells in a substantial part
of the AML patient population, but absent on normal CD34+CD38- cells, also after chemo‐
therapy [124,125]. For the other stem cell markers high specificity and stability during treat‐
ment/disease still have to be confirmed. The established differences in ALDH activity
between CD34+CD38- LSCs and CD34+CD38- HSCs were confirmed using this aberrant
marker approach [114,115], thereby strengthening that the functional ALDH assay offers an
alternative tool for CD34+CD38- LSC identification, which importantly, could be applied in
absence of aberrant antigen expression. In contrast, the SP phenotype does not discriminate
between HSCs and LSCs since both may be present in the SP compartment. Here the immu‐
nophenotypic marker approach is necessary to discriminate between LSCs and HSCs [121].
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Both ALDH and SP assays not only identify leukemia initiating cells with the CD34+CD38-
immunophenotype, but also other cell types, like CD34+CD38+ progenitors or CD34- cells
[114,115,117].
Although functional assays, like ALDH and SP, are complex and time-consuming compared
to standard immunophenotypic LSC detection, they may offer promising alternatives for
CD34+ AML patients without detectable CD34+CD38- cells, as well as for AML patients who
are defined as CD34 negative. The latter patients usually have less than 1% expression of
CD34 on the leukemic blast cells which all are of non-neoplastic origin [133]. However, also
for cases with CD34+CD38- LSCs present, these functionally defined compartments may be
important: since the frequency of SP cells is far lower compared to the frequency of
CD34+CD38- stem cells [121], an interesting possibility would be that combination of both as‐
says may narrow the real stem cell compartment [121]. In contrast to the immunophenotypic
definition, ALDH activity and dye efflux ability are likely directly related to drug response
and in that sense may predict which stem cells will survive therapy. Together with the ob‐
servations that immunophenotypically defined CD34+CD38- cells are in vitro therapy resist‐
ant too [104] and that most likely a CD34+CD38- subpopulation grows out to relapse [84], the
possibility that relapses are caused by functionally defined subpopulations of the
CD34+CD38- compartment can be suggested.
Antigen Function Reference
CLL-1 C-type lectin-like molecule-1 [125]
Lineage markers Lymphoid lineage and myeloid lineage markers [124]
CD25 Interleukin-2 receptor α-chain [126]
CD32 Fc fragement of IgG, low affinity IIa receptor [126]
CD33 Myeloid marker [127]
CD44 Receptor for hyaluronan [128]
CD47 Integrin associated protein [129]
CD96 T cell-activated increased late expression protein [130]
CD123 Interleukin 3 receptor alpha chain [131]
TIM-3 T-cell Ig mucin-3 [132]
Table 3. Overview of stem cell markers.
Seen the large clonal heterogeneity at diagnosis [84,101], and the possibility that not just the
major clone at diagnosis, but often low-frequency CD34+CD38- clones may grow out [84],
this suggests that identification of functionally defined minor subpopulations present at di‐
agnosis may offer clues how to predict relapse in a very early stage and thereby ultimately
how to circumvent such relapses.
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CD34+CD38- population was analyzed for the expression of six aberrant markers: CD2 (A),
CLL-1 (B), CD22 (C), CD96 (D), CD123 (E), CD11b (F). Expressions percentages for marker
positive and marker negative CD34+CD38- cells are shown for each marker.
Figure 4. Heterogeneity in expression of different stem cell markers in one AML case at diagnosis.
3.3. Prognostic value of LSC frequency
Since it has been hypothesized that the subpopulation of chemotherapy resistant LSCs is re‐
sponsible for relapse, LSC frequency, similar to MRD frequency, should have direct prog‐
nostic impact.
Van Rhenen et al. were the first to study the correlation between the frequency of
CD34+CD38- cells at diagnosis and clinical outcome in 92 AML patients. In a multivariate
analysis, including known risk factors, the frequency of the CD34+CD38- compartment (% of
blast cells) turned out to be an independent prognostic factor for RFS (p = 0.004) and DFS (p
= 0.05) [134]. In a small group of pediatric AML patients, Witte et al. found that the
CD34+CD38- subpopulation was significantly lower in patients with 5-year DFS (n = 8) com‐
pared to patients with relapse and/or death (n = 9) (0.45% ± 0.61% v. 1.52% ± 1.52%, p = 0.04)
[135]. Moreover, Hwang and colleagues have demonstrated, in a group of 54 AML patients,
that the proportion of CD34+CD38- cells at diagnosis was significantly lower in patients ach‐
ieving CR compared to patients who did not achieve CR (median 0.7% v. 6.9%, p = 0.006)
[136]. Lastly, using the ALDH activity assay, Ran et al. have shown a significant difference in
OS and RFS between patients with high and low LSC frequencies (OS, p = 0.04, RFS, p =
0.01). Multivariate Cox regression for OS showed LSC frequency and WBC count at diagno‐
sis to be the only significant prognostic factors (HR 10.5 for LSCs, p = 0.05), with borderline
significance for RFS (HR 3.8, p = 0.05) [118]. In our recent study we refined the definition
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used in aforementioned papers by including markers that enabled to discriminate LSC from
HSC [137]. In total, 101 patients were monitored for LSC frequency. Again, differences in
prognosis were found between patients groups defined by different cut offs (Table 4.)
Cut-off Number of patients above
cut-off
Relative risk of relapse 95% C.I.
First cycle 5 x 10-6 14 5.0 1.8-14.0
Second cycle 5 x 10-6 18 4.7 2.2-10.1
Consolidation 2 x 10-6 14 8.5 1.8-41.4
Table 4. Relative risk of relapse defined by LSC frequency [137].
All together, several studies showed CD34+CD38- LSC frequency to be an independent prog‐
nostic risk factor. Important to emphasize, however, is that these studies focus on LSC detec‐
tion and quantification at AML diagnosis. Because LSCs are hypothesized to be
chemotherapy resistant and to grow out after treatment and then cause a relapse, it would
be of utmost importance to study the frequency of these LSCs during follow-up. For the first
time we also demonstrated that the frequencies of LSCs after different courses of therapy
significantly correlated with clinical outcome [137]. More effort is needed to identify LSCs
and their prognostic value in immunophenotypic compartments other than CD34+CD38-,
like the CD34+CD38+ and CD34- compartment using the ALDH and SP assay. Ultimately,
when the clinical importance of different stem cell compartments have been prospectively
confirmed, this, together with MRD based strategies, should offer new diagnostic tools to
guide clinical intervention and to monitor effectiveness of therapy and, moreover, to design
new therapies that specifically target LSCs while leaving the normal HSCs intact.
3.4. Leukemic stem cell targeted therapy
Apart from the clinical application of LSCs, characterization of these malignant cells offers
the design of new therapies that specifically target LSCs while leaving the normal HSCs in‐
tact. The most direct example of such therapy is the application of antibodies that are used
to specifically discriminate between LSC and HSC. CD123 and CD33 are examples. It has
been reported, using NOD/SCID mice, that treatment with the anti-CD123 antibody 7G3 im‐
proved mouse survival [138]. A humanized version of the anti-CD123 antibody (CLS360)
has been studied in a phase 1 study in relapsed, refractory and high-risk AML patients. In‐
terim analysis showed no treatment related toxicity, besides two mild infusion reactions and
one infection possibly related to the treatment. Of eight patients treated with CLS360, one
CR had been observed [139]. Further clinical studies are needed to determine the efficacy of
this antibody in AML patients.
CD33 is expressed on leukemic blasts in 85%-90% of AML patients and therefore, already
years ago, it had been suggested as a potential target for anti-AML therapy. The CD33 im‐
munoconjugate gemtuzumab ozogamicin (Mylotarg) has been studied in several trials and,
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after initial disappointment relating to toxicity, new studies with altered treatment sched‐
ules suggest that Mylotarg is beneficial in certain subgroups of AML patients, including pa‐
tients with favorable cytogenetics [140]. However, it is important to emphasize that no
studies so far determined the correlation between the efficacy of Mylotarg and the presence
of CD33 positive LSCs. It may be speculated that subgroups of patients with CD33 positive
LSCs may benefit from this additional therapy. Further clinical trials will also have to deter‐
mine if other stem cell markers are potential targets as well.
4. Conclusions and future perspectives
MRD frequency assessments by RQ-PCR and MFC in AML patients are more sensitive
methods to define remission status compared to current morphologic assessment. Although
RQ-PCR is in general the most sensitive technique, MFC is applicable in almost all AML pa‐
tients. Since the importance of flow cytometric MRD detection has now been validated in a
first prospective study, it is of utmost importance that, when these data are confirmed in
other prospective studies, MRD status will be implemented in clinical decision-making. We
have described that alternatives for BM MRD may include MRD assessment in peripheral
blood and blast reduction, frequency of B-lymphocytes precursors and CD34+ myeloid/
lymphoid ratios. It thus seems that development of algorithms including all such parame‐
ters may ultimately contribute to improved detection of residual therapy resistant cells and
early and accurate prediction of relapses. Also, based on the observation of immunopheno‐
typic and molecular shifts, occurring between diagnosis and relapse, a new issue in MRD
research may be that not only disappearing phenotypes, but also emerging “new” pheno‐
types have to be monitored. An alternative, probably more specific method to predict clini‐
cal outcome is LSC frequency assessment. Results so far on the clinical importance of LSCs
are limited, but very promising, especially since for the first time the correlation between the
presence of LSCs after treatment and clinical outcome has been reported. When the value of
LSC assessment is confirmed in other retrospective and eventually prospective studies, it
may be hypothesized that in the future, not only MRD, but also LSC frequency assessment
may be implemented in clinical decision-making.
Hopefully, using the suggested approaches in this chapter, it will become possible to signifi‐
cantly improve clinical outcome of acute myeloid leukemia patients.
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